Omalizumab Therapy for Allergic Diseases
Pp. 118-161 (44)
Juan Antonio Martinez-Tadeo, Eva Perez-Rodriguez and Zulay Almeida-Sanchez
The antibody omalizumab is a humanized anti-IgE monoclonal binding to
IgE circulating preventing binding to receptors and thereby inhibiting the cascade of
allergic inflammation. Besides achieving a reduction in expression of IgE receptors on
the surface of basophils and expression of high affinity receptor for IgE on the surface
of dendritic cells. Its use has been approved for patients aged 6 years old with moderate
to severe allergic asthma, also has been effective in other diseases such as asthma of
occupational origin, seasonal or perennial allergic rhinitis, chronic urticaria difficult to
control and helping to better tolerance immunotherapy. The results obtained in different
studies on treatment with omalizumab in severe atopic dermatitis are contradictory.
While providing a promising effect in the treatment of food and drug allergy more longterm
studies are needed.
Omalizumab, asthma, IgE, antiIgE, food allergy, drug allergy, atopic
dermatitis, chronic urticaria, immunotherapy, mastocytosis.
Allergy and Immunology Service, Hospital Universitario Ntra. Sra. De Candelaria, Spain.